MedTrace Logo

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort

NCT04407689 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2022-04-08

No results posted yet for this study

Summary

Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/ kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.

Conditions

Interventions

DRUG

Interleukin-7

Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or

DRUG

Placebo

Intramuscular (IM) placebo (normal saline) at the same frequency

Sponsors & Collaborators

  • University Hospital, Limoges

    collaborator OTHER

  • Amarex Clinical Research

    collaborator OTHER

  • Revimmune

    lead INDUSTRY

Principal Investigators

  • Bruno François, MD · University Hospital, Limoges

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-08
Primary Completion
2022-03-30
Completion
2022-03-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04407689 on ClinicalTrials.gov